Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D Drug Price Policies May Offer Financial Trade-Offs

Executive Summary

Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.


Related Content

Generics, Budgeting, And The Stubborn Persistence Of Cost Savings
At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law
Mehta Analysis: How Buffett And Friends Can Succeed, And How Pharma Would Be Affected
Part D Coverage Gap Discounts Deepened To 70% In Budget Bill
Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA
Medicare May Require Part D Plans To Provide Point-of-Sale Rebates
Closed Formularies in Medicaid? Massachusetts Could Set Precedent
Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal
Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts